Nath Bio-Genes (India) Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 8, 2025, 11:16 am

Market Cap	302 Cr.
Current Price	159
High / Low	264/142
Stock P/E	7.24
Book Value	339
Dividend Yield	1.26 %
ROCE	6.85 %
ROE	6.23 %
Face Value	10.0
PEG Ratio	-1.40

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Nath Bio-Genes (India) Ltd

Competitors of Nath Bio-Genes (India) Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Genomic Valley Biotech Ltd	17.7 Cr.	58.0	108/28.4	44.3	12.5	0.00 %	0.57 %	0.57 %	10.0
Genesis IBRC India Ltd	23.8 Cr.	18.3	18.3/10.2		6.58	0.00 %	54.8 %	54.8 %	10.0
Shreeoswal Seeds & Chemicals Ltd	123 Cr.	13.5	40.8/12.4		4.13	0.00 %	0.62 %	9.84 %	2.00
Nath Bio-Genes (India) Ltd	302 Cr.	159	264/142	7.24	339	1.26 %	6.85 %	6.23 %	10.0
Continental Seeds and Chemicals Ltd	36.4 Cr.	33.1	70.2/20.9		21.8	0.00 %	10.0 %	18.0 %	10.0
Industry Average	212.50 Cr	56.38		25.77	76.80	0.25%	14.57%	17.89%	8.40

All Competitor Stocks of Nath Bio-Genes (India) Ltd

Quarterly Result

Metric	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	21.94	27.21	209.39	21.73	25.30	44.92	235.28	22.57	31.74	43.04	243.88	32.19	36.87
Expenses	15.65	48.47	174.91	16.98	19.68	40.84	198.26	17.48	25.96	38.57	206.82	25.63	29.36
Operating Profit	6.29	-21.26	34.48	4.75	5.62	4.08	37.02	5.09	5.78	4.47	37.06	6.56	7.51
OPM %	28.67%	-78.13%	16.47%	21.86%	22.21%	9.08%	15.73%	22.55%	18.21%	10.39%	15.20%	20.38%	20.37%
Other Income	0.00	-88.05	0.00	0.20	0.06	0.26	0.12	0.06	2.54	1.39	0.14	0.07	0.48
Interest	2.70	2.47	2.88	2.75	2.96	1.53	2.76	2.44	2.84	1.06	2.24	2.94	3.37
Depreciation	0.68	1.05	0.67	0.67	0.67	0.99	0.76	0.76	0.76	0.98	0.83	0.83	0.83
Profit before tax	2.91	-112.83	30.93	1.53	2.05	1.82	33.62	1.95	4.72	3.82	34.13	2.86	3.79
Tax %	3.44%	3.07%	0.55%	3.92%	34.15%	12.64%	0.65%	17.95%	16.31%	16.23%	0.73%	-1.05%	30.08%
Net Profit	2.81	-116.29	30.76	1.47	1.35	1.59	33.40	1.61	3.96	3.21	33.89	2.89	2.66
EPS in Rs	1.48	-61.19	16.19	0.77	0.71	0.84	17.58	0.85	2.08	1.69	17.83	1.52	1.40

Last Updated: February 28, 2025, 6:13 pm

Below is a detailed analysis of the quarterly data for Nath Bio-Genes (India) Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is ₹36.87 Cr.. The value appears strong and on an upward trend. It has increased from 32.19 Cr. (Sep 2024) to ₹36.87 Cr., marking an increase of ₹4.68 Cr..
For Expenses, as of Dec 2024, the value is ₹29.36 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 25.63 Cr. (Sep 2024) to ₹29.36 Cr., marking an increase of ₹3.73 Cr..
For Operating Profit, as of Dec 2024, the value is ₹7.51 Cr.. The value appears strong and on an upward trend. It has increased from 6.56 Cr. (Sep 2024) to ₹7.51 Cr., marking an increase of ₹0.95 Cr..
For OPM %, as of Dec 2024, the value is 20.37%. The value appears to be declining and may need further review. It has decreased from 20.38% (Sep 2024) to 20.37%, marking a decrease of 0.01%.
For Other Income, as of Dec 2024, the value is ₹0.48 Cr.. The value appears strong and on an upward trend. It has increased from 0.07 Cr. (Sep 2024) to ₹0.48 Cr., marking an increase of ₹0.41 Cr..
For Interest, as of Dec 2024, the value is ₹3.37 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.94 Cr. (Sep 2024) to ₹3.37 Cr., marking an increase of ₹0.43 Cr..
For Depreciation, as of Dec 2024, the value is ₹0.83 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.83 Cr..
For Profit before tax, as of Dec 2024, the value is ₹3.79 Cr.. The value appears strong and on an upward trend. It has increased from 2.86 Cr. (Sep 2024) to ₹3.79 Cr., marking an increase of ₹0.93 Cr..
For Tax %, as of Dec 2024, the value is 30.08%. The value appears to be increasing, which may not be favorable. It has increased from -1.05% (Sep 2024) to 30.08%, marking an increase of 31.13%.
For Net Profit, as of Dec 2024, the value is ₹2.66 Cr.. The value appears to be declining and may need further review. It has decreased from 2.89 Cr. (Sep 2024) to ₹2.66 Cr., marking a decrease of 0.23 Cr..
For EPS in Rs, as of Dec 2024, the value is 1.40. The value appears to be declining and may need further review. It has decreased from ₹1.52 (Sep 2024) to 1.40, marking a decrease of ₹0.12.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 3:24 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	109	136	143	127	142	171	206	246	271	230	234	248	356
Expenses	89	102	109	103	113	131	163	191	204	193	185	197	300
Operating Profit	20	34	35	25	29	40	43	55	67	37	49	50	56
OPM %	18%	25%	24%	19%	20%	24%	21%	22%	25%	16%	21%	20%	16%
Other Income	1	1	1	1	0	1	2	2	2	-87	1	4	2
Interest	4	4	5	6	10	10	5	7	9	11	10	9	10
Depreciation	5	5	4	4	3	1	1	1	3	3	3	3	3
Profit before tax	12	26	26	15	17	30	39	49	57	-63	36	42	45
Tax %	4%	5%	4%	6%	3%	2%	1%	-4%	2%	6%	3%	5%
Net Profit	12	24	25	14	16	29	38	50	56	-67	35	40	43
EPS in Rs	7.34	15.18	15.87	8.85	10.17	15.48	20.22	26.56	29.29	-35.43	18.51	21.14	22.44
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	7%	-6%	11%	9%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	100.00%	4.17%	-44.00%	14.29%	81.25%	31.03%	31.58%	12.00%	-219.64%	152.24%	14.29%
Change in YoY Net Profit Growth (%)	0.00%	-95.83%	-48.17%	58.29%	66.96%	-50.22%	0.54%	-19.58%	-231.64%	371.88%	-137.95%

Nath Bio-Genes (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: January 13, 2025, 3:10 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	16	16	16	16	16	19	19	19	19	19	19	19	19
Reserves	41	66	91	105	287	450	489	539	594	523	554	592	624
Borrowings	19	23	22	59	74	33	58	70	101	93	105	108	127
Other Liabilities	67	85	97	87	78	69	80	102	75	105	114	158	58
Total Liabilities	143	190	226	267	455	571	646	730	790	740	793	877	829
Fixed Assets	18	17	13	30	207	211	232	246	247	245	244	249	251
CWIP	0	0	0	0	0	0	0	0	0	0	0	0	0
Investments	5	5	5	5	5	5	5	5	5	5	5	6	6
Other Assets	120	168	208	231	243	355	409	479	538	490	544	622	572
Total Assets	143	190	226	267	455	571	646	730	790	740	793	877	829

Below is a detailed analysis of the balance sheet data for Nath Bio-Genes (India) Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹19.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹19.00 Cr..
For Reserves, as of Sep 2024, the value is ₹624.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹592.00 Cr. (Mar 2024) to ₹624.00 Cr., marking an increase of 32.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹127.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from ₹108.00 Cr. (Mar 2024) to ₹127.00 Cr., marking an increase of 19.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹58.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹158.00 Cr. (Mar 2024) to ₹58.00 Cr., marking a decrease of 100.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹829.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹877.00 Cr. (Mar 2024) to ₹829.00 Cr., marking a decrease of 48.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹251.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹249.00 Cr. (Mar 2024) to ₹251.00 Cr., marking an increase of 2.00 Cr..
For CWIP, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
For Investments, as of Sep 2024, the value is ₹6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹6.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹572.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹622.00 Cr. (Mar 2024) to ₹572.00 Cr., marking a decrease of 50.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹829.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹877.00 Cr. (Mar 2024) to ₹829.00 Cr., marking a decrease of 48.00 Cr..

Notably, the Reserves (₹624.00 Cr.) exceed the Borrowings (127.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

No data available for this post.

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	1.00	11.00	13.00	-34.00	-45.00	7.00	-15.00	-15.00	-34.00	-56.00	-56.00	-58.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	70	95	114	130	133	175	191	159	147	136	152	139
Inventory Days					3,840	4,743					4,388
Days Payable					1,309	1,406					586
Cash Conversion Cycle	70	95	114	130	2,665	3,512	191	159	147	136	3,954	139
Working Capital Days	167	179	242	383	398	515	544	519	585	573	578	498
ROCE %	24%	33%	26%	14%	10%	9%	8%	9%	10%	5%	7%	7%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	41.05%	41.07%	45.59%	45.59%	45.59%	45.59%	45.59%	45.59%	45.59%	45.59%	45.59%	45.59%
FIIs	0.07%	0.11%	0.01%	0.15%	0.13%	0.07%	0.22%	0.32%	0.27%	0.21%	0.18%	0.19%
DIIs	4.85%	4.62%	4.62%	4.62%	4.62%	4.62%	4.37%	4.37%	4.37%	4.37%	4.37%	4.37%
Public	54.02%	54.20%	49.77%	49.62%	49.65%	49.71%	49.81%	49.72%	49.76%	49.80%	49.83%	49.83%
No. of Shareholders	35,610	35,484	35,470	34,749	33,960	33,502	34,365	34,263	35,132	35,834	35,423	35,056

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Aditya Birla Sun Life Pure Value Fund	828,595	0.32	16.53	828,595	2025-03-06	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 13	Mar 12
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	19.52	18.43	-35.55	7.34	5.75
Diluted EPS (Rs.)	19.52	18.43	-35.55	7.34	5.75
Cash EPS (Rs.)	22.56	20.01	-33.84	10.16	8.69
Book Value[Excl.RevalReserv]/Share (Rs.)	320.94	301.60	285.16	35.91	28.57
Book Value[Incl.RevalReserv]/Share (Rs.)	320.94	301.60	285.16	35.91	28.57
Revenue From Operations / Share (Rs.)	175.03	158.58	146.47	86.04	77.43
PBDIT / Share (Rs.)	26.57	25.94	20.54	12.80	10.61
PBIT / Share (Rs.)	24.85	24.36	18.92	9.98	7.67
PBT / Share (Rs.)	21.87	19.03	-33.38	7.68	6.54
Net Profit / Share (Rs.)	20.85	18.42	-35.46	7.34	5.75
NP After MI And SOA / Share (Rs.)	20.85	18.42	-35.46	7.34	5.75
PBDIT Margin (%)	15.17	16.35	14.02	14.87	13.70
PBIT Margin (%)	14.19	15.35	12.91	11.59	9.90
PBT Margin (%)	12.49	12.00	-22.78	8.92	8.45
Net Profit Margin (%)	11.91	11.61	-24.20	8.52	7.42
NP After MI And SOA Margin (%)	11.91	11.61	-24.20	8.52	7.42
Return on Networth / Equity (%)	6.49	6.10	-12.43	20.43	20.12
Return on Capital Employeed (%)	7.64	8.03	6.59	26.54	25.62
Return On Assets (%)	4.50	4.41	-9.11	7.42	7.67
Long Term Debt / Equity (X)	0.01	0.00	0.00	0.02	0.01
Total Debt / Equity (X)	0.18	0.18	0.17	0.31	0.19
Asset Turnover Ratio (%)	0.39	0.39	0.00	1.05	0.00
Current Ratio (X)	2.18	2.41	2.41	1.22	1.34
Quick Ratio (X)	1.30	1.45	1.27	0.43	0.42
Dividend Payout Ratio (NP) (%)	9.59	10.85	-5.64	0.00	0.00
Dividend Payout Ratio (CP) (%)	8.86	9.99	-5.91	0.00	0.00
Earning Retention Ratio (%)	90.41	89.15	105.64	0.00	0.00
Cash Earning Retention Ratio (%)	91.14	90.01	105.91	0.00	0.00
Interest Coverage Ratio (X)	5.54	4.87	3.68	5.58	9.40
Interest Coverage Ratio (Post Tax) (X)	4.97	4.46	3.02	4.20	6.87
Enterprise Value (Cr.)	363.13	336.48	494.22	0.00	0.00
EV / Net Operating Revenue (X)	1.09	1.12	1.78	0.00	0.00
EV / EBITDA (X)	7.19	6.83	12.66	0.00	0.00
MarketCap / Net Operating Revenue (X)	0.99	0.89	1.46	0.00	0.00
Retention Ratios (%)	90.40	89.14	105.64	0.00	0.00
Price / BV (X)	0.54	0.46	0.74	0.00	0.00
Price / Net Operating Revenue (X)	0.99	0.89	1.46	0.00	0.00
EarningsYield	0.11	0.13	-0.16	0.00	0.00

After reviewing the key financial ratios for Nath Bio-Genes (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 24, the value is 19.52. This value is within the healthy range. It has increased from 18.43 (Mar 23) to 19.52, marking an increase of 1.09.
For Diluted EPS (Rs.), as of Mar 24, the value is 19.52. This value is within the healthy range. It has increased from 18.43 (Mar 23) to 19.52, marking an increase of 1.09.
For Cash EPS (Rs.), as of Mar 24, the value is 22.56. This value is within the healthy range. It has increased from 20.01 (Mar 23) to 22.56, marking an increase of 2.55.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 320.94. It has increased from 301.60 (Mar 23) to 320.94, marking an increase of 19.34.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 320.94. It has increased from 301.60 (Mar 23) to 320.94, marking an increase of 19.34.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 175.03. It has increased from 158.58 (Mar 23) to 175.03, marking an increase of 16.45.
For PBDIT / Share (Rs.), as of Mar 24, the value is 26.57. This value is within the healthy range. It has increased from 25.94 (Mar 23) to 26.57, marking an increase of 0.63.
For PBIT / Share (Rs.), as of Mar 24, the value is 24.85. This value is within the healthy range. It has increased from 24.36 (Mar 23) to 24.85, marking an increase of 0.49.
For PBT / Share (Rs.), as of Mar 24, the value is 21.87. This value is within the healthy range. It has increased from 19.03 (Mar 23) to 21.87, marking an increase of 2.84.
For Net Profit / Share (Rs.), as of Mar 24, the value is 20.85. This value is within the healthy range. It has increased from 18.42 (Mar 23) to 20.85, marking an increase of 2.43.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 20.85. This value is within the healthy range. It has increased from 18.42 (Mar 23) to 20.85, marking an increase of 2.43.
For PBDIT Margin (%), as of Mar 24, the value is 15.17. This value is within the healthy range. It has decreased from 16.35 (Mar 23) to 15.17, marking a decrease of 1.18.
For PBIT Margin (%), as of Mar 24, the value is 14.19. This value is within the healthy range. It has decreased from 15.35 (Mar 23) to 14.19, marking a decrease of 1.16.
For PBT Margin (%), as of Mar 24, the value is 12.49. This value is within the healthy range. It has increased from 12.00 (Mar 23) to 12.49, marking an increase of 0.49.
For Net Profit Margin (%), as of Mar 24, the value is 11.91. This value exceeds the healthy maximum of 10. It has increased from 11.61 (Mar 23) to 11.91, marking an increase of 0.30.
For NP After MI And SOA Margin (%), as of Mar 24, the value is 11.91. This value is within the healthy range. It has increased from 11.61 (Mar 23) to 11.91, marking an increase of 0.30.
For Return on Networth / Equity (%), as of Mar 24, the value is 6.49. This value is below the healthy minimum of 15. It has increased from 6.10 (Mar 23) to 6.49, marking an increase of 0.39.
For Return on Capital Employeed (%), as of Mar 24, the value is 7.64. This value is below the healthy minimum of 10. It has decreased from 8.03 (Mar 23) to 7.64, marking a decrease of 0.39.
For Return On Assets (%), as of Mar 24, the value is 4.50. This value is below the healthy minimum of 5. It has increased from 4.41 (Mar 23) to 4.50, marking an increase of 0.09.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.01. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 23) to 0.01, marking an increase of 0.01.
For Total Debt / Equity (X), as of Mar 24, the value is 0.18. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 0.18.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.39. There is no change compared to the previous period (Mar 23) which recorded 0.39.
For Current Ratio (X), as of Mar 24, the value is 2.18. This value is within the healthy range. It has decreased from 2.41 (Mar 23) to 2.18, marking a decrease of 0.23.
For Quick Ratio (X), as of Mar 24, the value is 1.30. This value is within the healthy range. It has decreased from 1.45 (Mar 23) to 1.30, marking a decrease of 0.15.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 9.59. This value is below the healthy minimum of 20. It has decreased from 10.85 (Mar 23) to 9.59, marking a decrease of 1.26.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 8.86. This value is below the healthy minimum of 20. It has decreased from 9.99 (Mar 23) to 8.86, marking a decrease of 1.13.
For Earning Retention Ratio (%), as of Mar 24, the value is 90.41. This value exceeds the healthy maximum of 70. It has increased from 89.15 (Mar 23) to 90.41, marking an increase of 1.26.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 91.14. This value exceeds the healthy maximum of 70. It has increased from 90.01 (Mar 23) to 91.14, marking an increase of 1.13.
For Interest Coverage Ratio (X), as of Mar 24, the value is 5.54. This value is within the healthy range. It has increased from 4.87 (Mar 23) to 5.54, marking an increase of 0.67.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 4.97. This value is within the healthy range. It has increased from 4.46 (Mar 23) to 4.97, marking an increase of 0.51.
For Enterprise Value (Cr.), as of Mar 24, the value is 363.13. It has increased from 336.48 (Mar 23) to 363.13, marking an increase of 26.65.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.09. This value is within the healthy range. It has decreased from 1.12 (Mar 23) to 1.09, marking a decrease of 0.03.
For EV / EBITDA (X), as of Mar 24, the value is 7.19. This value is within the healthy range. It has increased from 6.83 (Mar 23) to 7.19, marking an increase of 0.36.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 0.99. This value is below the healthy minimum of 1. It has increased from 0.89 (Mar 23) to 0.99, marking an increase of 0.10.
For Retention Ratios (%), as of Mar 24, the value is 90.40. This value exceeds the healthy maximum of 70. It has increased from 89.14 (Mar 23) to 90.40, marking an increase of 1.26.
For Price / BV (X), as of Mar 24, the value is 0.54. This value is below the healthy minimum of 1. It has increased from 0.46 (Mar 23) to 0.54, marking an increase of 0.08.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 0.99. This value is below the healthy minimum of 1. It has increased from 0.89 (Mar 23) to 0.99, marking an increase of 0.10.
For EarningsYield, as of Mar 24, the value is 0.11. This value is below the healthy minimum of 5. It has decreased from 0.13 (Mar 23) to 0.11, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Nath Bio-Genes (India) Ltd as of March 12, 2025 is: ₹123.87

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Nath Bio-Genes (India) Ltd is Overvalued by 22.09% compared to the current share price 159.00

Intrinsic Value of Nath Bio-Genes (India) Ltd as of March 12, 2025 is: 117.44

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Nath Bio-Genes (India) Ltd is Overvalued by 26.14% compared to the current share price 159.00

Last 5 Year EPS CAGR: -5.19%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has higher reserves (381.15 cr) compared to borrowings (68.62 cr), indicating strong financial stability. The company has shown consistent growth in sales (201.46 cr) and profit (25.46 cr) over the years.	The stock has a low average ROCE of 13.50%, which may not be favorable. The stock has a high average Working Capital Days of 431.75, which may not be favorable. The stock has a high average Cash Conversion Cycle of 99.08, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Nath Bio-Genes (India) Ltd:
1. Net Profit Margin: 11.91%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 7.64% (Industry Average ROCE: 14.57%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 6.49% (Industry Average ROE: 17.89%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 4.97
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.3
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 7.24 (Industry average Stock P/E: 25.77)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.18
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Nath Bio-Genes (India) Ltd. is a Public Limited Listed company incorporated on 14/07/1993 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L01110MH1993PLC072842 and registration number is 072842. Currently Company is involved in the business activities of Growing of non-perennial crops. Company's Total Operating Revenue is Rs. 332.62 Cr. and Equity Capital is Rs. 19.00 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Seeds/Tissue Culture/Bio Technology	Nath House, Nath Road, Aurangabad Maharashtra 431005	investor@nathbiogenes.com http://www.nathbiogenes.com

Management
Name	Position Held
Mr. Satish Kagliwal	Managing Director
Mr. Madhukar Deshpande	Director
Ms. Ashu Jain	Director
Mrs. Jeevanlata Kagliwal	Director
Mr. Vadla Nagabhushanam	Director
Mr. Hitesh Purohit	Director
Mr. Akash Kagliwal	Director

FAQ

What is the latest intrinsic value of Nath Bio-Genes (India) Ltd?

The latest intrinsic value of Nath Bio-Genes (India) Ltd as on 09 March 2025 is ₹123.87, which is 22.09% lower than the current market price of 159.00, indicating the stock is overvalued by 22.09%. The intrinsic value of Nath Bio-Genes (India) Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹302 Cr. and recorded a high/low of ₹264/142 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹624 Cr and total liabilities of ₹829 Cr.

What is the Market Cap of Nath Bio-Genes (India) Ltd?

The Market Cap of Nath Bio-Genes (India) Ltd is 302 Cr..

What is the current Stock Price of Nath Bio-Genes (India) Ltd as on 09 March 2025?

The current stock price of Nath Bio-Genes (India) Ltd as on 09 March 2025 is ₹159.

What is the High / Low of Nath Bio-Genes (India) Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Nath Bio-Genes (India) Ltd stocks is ₹264/142.

What is the Stock P/E of Nath Bio-Genes (India) Ltd?

The Stock P/E of Nath Bio-Genes (India) Ltd is 7.24.

What is the Book Value of Nath Bio-Genes (India) Ltd?

The Book Value of Nath Bio-Genes (India) Ltd is 339.

What is the Dividend Yield of Nath Bio-Genes (India) Ltd?

The Dividend Yield of Nath Bio-Genes (India) Ltd is 1.26 %.

What is the ROCE of Nath Bio-Genes (India) Ltd?

The ROCE of Nath Bio-Genes (India) Ltd is 6.85 %.

What is the ROE of Nath Bio-Genes (India) Ltd?

The ROE of Nath Bio-Genes (India) Ltd is 6.23 %.

What is the Face Value of Nath Bio-Genes (India) Ltd?

The Face Value of Nath Bio-Genes (India) Ltd is 10.0.